|Title:||Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer||Authors:||JHE-CYUAN GUO
|Keywords:||differential response; esophageal squamous cell carcinoma; immune checkpoint inhibitor; immune contexture; tumor site specific||Issue Date:||20-Jun-2023||Source:||Thoracic cancer||Abstract:||
Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more than 6 months except primary resistant esophageal tumor. The esophageal tumor had higher regulatory T cells, neutrophils, and mast cells scores estimated by NanoString platform than hepatic tumor. The immunohistochemistry study confirmed higher expression levels of Foxp3, and myeloperoxidase (MPO) in the esophageal tumor. The different immune contextures may underlie the heterogeneous responses to ICI combination in this ESCC patient.
|Appears in Collections:||腫瘤醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.